Drug Discovery and ResistanceHigh-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv
Section snippets
Bacterial strain, growth conditions and media
M. tuberculosis H37Rv (ATCC 27294) was obtained from the American Type Culture Collection (Manassas, VA). To prepare permanent frozen stocks, H37Rv was grown as five mL subcultures (50 mL conical tubes, 36–37 °C) in Middlebrook 7H9 broth (Becton Dickinson) supplemented with 0.2% glycerol (Becton Dickinson), 0.05% Tween 80 (Becton Dickinson), and 10% ADC enrichment (albumin, dextrose, catalase; Becton Dickinson). The subculture was mixed periodically and used to inoculate (5% inoculum) a second
Assay validation
The assay for H37Rv22 was miniaturized to 384-well format. Initially, experiments were run in 96- and 384-well formats to ensure that the conversion to 384-well plates yielded similar results. CV% for media only, M. tuberculosis, and M. tuberculosis plus either 10 μg/mL ethambutol or 2.5 μg/mL amikacin were <10%. Z-values calculated for either M. tuberculosis alone or M. tuberculosis plus either 10 μg/mL ethambutol or 2.5 μg/mL amikacin were usually >0.7 and were equivalent in either 96- or
Discussion
In an effort to identify specific classes of compounds that show significant antitubercular activity, a structure based clustering analysis was performed on the set of compounds that was considered active with TB IC90 value of less than 10 μg/mL. The clustering analysis was performed using a hierarchical clustering method as implemented in LeadScope (LeadScope, Inc.) to identify common structural elements among this diverse set of structures. Clusters were separated using the ‘Complete Linkage
Conclusions
The discovery of new lead compounds active against M. tuberculosis is only the initial step in the development of a new antitubercular drug. Analysis of cytotoxicity is a rudimentary measure of potential toxicity, but can serve to prioritize compounds for further study. Additional in vitro evaluations that would provide useful information are 1) the evaluation of activity against other non-mycobacterial bacterial pathogens for identification of TB-specific drugs; 2) evaluation of bactericidal
Acknowledgments
This work was supported by contracts N01-AI-95364 (JAS) and N01-AI-15449 (ELW). The complete data sets for the HTS campaign will be deposited in PubChem. The authors thank Dr. Scott Franzblau who generously provided us with his protocol for the Alamar Blue M. tuberculosis assay at the beginning of this program. The authors are appreciative of the assistance of Sara McKellip, Nicole Kushner and Kristen Southworth in running the H37Rv screen, Anna Manouvakhova for assistance in the data analysis
References (137)
- et al.
Tuberculosis trends in the United States, 1992–2001
Tuberculosis (Edinb)
(2003) Progress in TB drug development and what is still needed
Tuberculosis (Edinb)
(2003)The global situation of MDR-TB
Tuberculosis (Edinb)
(2003)- et al.
Predicting the future of XDR tuberculosis
Lancet Infect Dis
(2007) - et al.
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Lancet
(2006) - et al.
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
Adv Drug Delivery Rev
(1997) - et al.
Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis
Bioorg Med Chem
(2004) - et al.
Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3 H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations
Bioorg Med Chem
(2005) - et al.
Synthesis and antimycobacterial activity of some alkyl [5-(nitroaryl)-1,3,4-thiadiazol-2-ylthio]propionates
Bioorg Med Chem Lett
(2006) - et al.
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents
Eur J Med Chem
(2008)
Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1α prolyl hydroxylase inhibitors
Bioorg Med Chem Lett
Substituted 4-methylquinolines as a new class of anti-tuberculosis agents
Bioorg Med Chem Lett
Ring-substituted quinolines as potential anti-tuberculosis agents
Bioorg Med Chem
Synthesis and antimycobacterial activities of ring-substituted quinolinecarboxylic acid/ester analogues. Part 1
Bioorg Med Chem
3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents
Bioorg Med Chem
Synthesis, anti-tuberculosis activity, and 3D-QSAR study of ring-substituted-2/4-quinolinecarbaldehyde derivatives
Bioorg Med Chem
Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-subtituted quinolines
Bioorg & Med Chem
Synthesis and structural–activity relationships of 3-hydroxyquinazoline-2,4-dione antibacterial agents
Bioorg Med Chem Lett
Synthesis, antitubercular and anticancer activities of substituted furyl-quinazolin-3(4H)-ones
Arch Pharm Chem Life Sci
Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening
Br J Pharmacol
Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis
Phytomedicine
Synthesis and biological evaluation of novel 1,4-naphthoquinone derivatives as antibacterial and antiviral agents
Bioorg Med Chem Lett
Synthesis and biological evaluation of novel (l)-α-amino acid methyl ester, heteroalkyl, and aryl substituted 1,4-naphthoquinone derivatives as antifungal and antibacterial agents
Bioorg Med Chem Lett
Ubiquinone synthesis and its regulation in Pneumocystis carinii
J Eukaryot Microbiol
Type II NADH:menaquinone oxidoreductase of Mycobacterium tuberculosis
Infect Disord – Drug Targets
Electron transfer kinetics and mechanistic study of the thionicotinamide coordinated to the pentacyanoferrate (III)/(II) complexes: a model system for the in vitro activation of thioamides anti-tuberculosis drugs
J Inorg Biochem
Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3
Chem Res Toxicol
Synthesis and antimicrobial activity of N-(substituted)-N′-(2,3-dihydro-2-oxido-5-benzoyl-1H-1,3,2-benzodiazaphosphol-2-yl) ureas
Chem Pharm Bull
Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery
Med Res Rev
Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors
Bioorg Med Chem Lett
Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure–activity relationships, and preliminary pharmacokinetics
Bioorg Med Chem Lett
A protein kinase inhibitor as an antimycobacterial agent
FEMS Microbiol Lett
The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis
Trends Microbiol
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure–activity relationships of the nucleobase domain of 5′-O-[N-salicylsulfamoyl]adenosine
J Med Chem
Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis
Antimicrob Agents Chemother
Programs to facilitate tuberculosis drug discovery: the Tuberculosis Antimicrobial Acquisition and Coordinating Facility
Infect Disord – Drug Targets
Global Tuberculosis Control 2008
Extensively drug-resistant Mycobacterium tuberculosis, India
Emerg Infect Dis
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness
Nat Med
Extensively drug-resistant tuberculosis in California, 1993–2006
Clin Infect Dis
Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases
BMC Infect Dis
Treatment outcomes in extensively resistant tuberculosis
N Engl J Med
Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis
Clin Infect Dis
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Eur Respir J
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Eur Respir J
Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results
Clin Infect Dis
Extensively drug-resistant tuberculosis, Italy and Germany
Emerg Infect Dis
Comprehensive treatment of extensively drug-resistant tuberculosis
N Engl J Med
Facing extensively drug-resistant tuberculosis – a hope and a challenge
N Engl J Med
New tuberculosis therapeutics: a growing pipeline
J Infect Dis
Cited by (252)
The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway
2024, European Journal of Medicinal ChemistryTargeting polyketide synthase 13 for the treatment of tuberculosis
2023, European Journal of Medicinal ChemistryOvercoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis
2022, Acta Pharmaceutica Sinica BChallenges in targeting mycobacterial ATP synthase: The known and beyond
2022, Journal of Molecular StructureMedicinal plants in antimicrobial resistance—Perspectives towards drug development
2022, Evidence-Based Validation of Herbal Medicine: Translational Research on Botanicals
- d
Tel.: +1 205 581 2822; fax: +1 205 581 2726.
- e
Tel.: +1 205 581 2761.
- f
Tel.: +1 205 581 2746.
- g
Tel.: +1 205 581 2748.
- h
Tel.: +1 205 581 2111.
- i
Tel.: +1 205 581 2259.
- j
Tel.: +1 205 581 2454.
- k
Tel.: +1 205 581 2709.
- l
Tel.: +1 205 581 2440.
- m
Tel.: +1 205 581 2558.
- n
Tel.: +1 205 581 2344.
- o
Tel.: +1 301 694 3232x282; fax: +1 301 694 7223.
- p
Tel.: +1 301 694 3232x283.
- q
Present address: 6610 Rockledge Drive, Room 5083, MSC 6603, Bethesda, MD 20817, USA. +1 301 496 8424; fax: +1 301 451 5481.
- r
Present address: 6610 Rockledge Drive, Room 4207, Bethesda, MD 20892 USA. Tel.: +1 301 402 0138.